Oncology Medical News about gynecologic cancer

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cancer treatment adherence among low-income women with breast or gynecologic cancer
Cancer, 07/01/09

Ell K et al. - Among gynecologic patients, 87% of the EUC group and 94% of the TPN group completed chemotherapy (41% of the EUC group and 31% of the TPN group completed it with delays), 7% of the EUC group and 6% of the TPN group failed to complete chemotherapy, 6% of the EUC refused chemotherapy, 87% of the EUC group and 84% of the TPN group completed radiation (51% of the EUC group and 42% of the TPN with delays), 5% of the EUC group and 8% of the TPN group failed to complete radiation, and 8% of the EUC group and 5% of the TPN group refused radiation.

<< Previous
Pulmonary neuroendocrine/carcinoid tumors

Next >>
Race does not impact outcome for advanced ovarian cancer patients...

Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations
Climacteric, 11/16/09 Relevance Score: 69%

Preventing future cancers by testing women with ovarian cancer for brca mutations
Journal of Clinical Oncology, 10/22/09 Relevance Score: 68%

Endometrial Cancer
American Family Physician, 11/12/09 Relevance Score: 67%

The Impacts of ERCC1 Gene Exon VIII Alternative Splicing on Cisplatin-Resistance in Ovarian Cancer Cells
Cancer Investigation, 10/26/09 Relevance Score: 67%

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
Journal of Clinical Oncology, 10/16/09 Relevance Score: 67%